close

Kurt G. Briscoe devotes his practice to patent prosecution, focusing primarily on the chemical, pharmaceutical, and biotechnology arts.

Recognized as an “outstanding” patent examiner while previously employed at the United States Patent and Trademark Office, Kurt brings more than 35 years of experience both inside and outside of government. One U.S. in-house intellectual property counsel writes, “[w]e had a very complicated and challenging case that was assigned to a difficult examiner. * * * Ultimately Kurt was able to persuade the examiner to allow claims that were broader than we were expecting, and the inventor and business department were very pleased.” One European patent attorney client describes Kurt as “getting even those cases allowed that had been considered unpatentable.” The Chief Operating Officer of one pharmaceutical company describes Kurt as “simply the best patent attorney I’ve ever worked with.” Don’t you want to focus that level of experience and competence on your important patent prosecution matters?

Kurt’s areas of technical expertise include organic syntheses, heterocyclic chemistry, pharmaceuticals, including Hatch-Waxman, adhesives, rubber technologies, catalysis, surfactants, personal care, home care, medical devices, dental devices, and light mechanical devices.

 Save as PDF
  • AIA Strategies.” Germany, May 6-12, 2012
  • Are Genes Patentable?,” Yorktown Bar Association, May 25, 2011
  • “Software and Business Method Patents: A Defensive & Offensive Strategy,” Minority Corporate Counsel Association (MCCA) 5th Annual CLE Expo, March 15-17, 2006
  • U.S. Serial No. 14/869,026, Notice of Allowance mailed September 15, 2021, after positive Conference Decision on Request for Pre-Appeal Brief Review
  • U.S. Serial No. 16/364,495, Decision of Patent Trial and Appeal Board dated August 27, 2021, reversing the examiner’s final rejection
  • U.S. Serial No. 15/257,079, Decision of Patent Trial and Appeal Board dated August 20, 2021, reversing the examiner’s final rejection
  • U.S. Serial No. 13/503,237, Decision of Patent Trial and Appeal Board dated May 28, 2021, reversing the examiner’s final rejection
  • U.S. Serial No. 16/654,389, Notice of Allowance mailed November 24, 2020, after filing of Appeal Brief

Contact This Attorney

  • This field is for validation purposes and should be left unchanged.